These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11177100)

  • 1. Cost estimates of prophylaxis.
    Moler F
    Arch Pediatr Adolesc Med; 2001 Feb; 155(2):199-200. PubMed ID: 11177100
    [No Abstract]   [Full Text] [Related]  

  • 2. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory syncytial virus PREVENT Study questions.
    Raju TN
    Pediatrics; 1997 Dec; 100(6):1044; author reply 1045. PubMed ID: 9411386
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of local guidelines for prevention of respiratory syncytial viral infections.
    Hall CB; Stevens TP; Swantz RJ; Sinkin RA; McBride JT
    Pediatr Infect Dis J; 1999 Oct; 18(10):850-3. PubMed ID: 10530578
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunoprophylaxis of respiratory syncytial virus infection.
    Simoes EA
    Indian Pediatr; 2000 Mar; 37(3):243-7. PubMed ID: 10750065
    [No Abstract]   [Full Text] [Related]  

  • 6. RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure?
    Moler FW
    Pediatrics; 1999 Sep; 104(3 Pt 1):559-60. PubMed ID: 10469785
    [No Abstract]   [Full Text] [Related]  

  • 7. [Is it smart to give immunoglobulin prophylaxis against respiratory syncytial virus infection?].
    Greisen G
    Ugeskr Laeger; 2001 Nov; 163(47):6607. PubMed ID: 11760548
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Mahadevia PJ; Malinoski FJ
    Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
    [No Abstract]   [Full Text] [Related]  

  • 9. Respiratory syncytial virus: babies and antibodies.
    Hemming VG; Prince GA
    Infect Agents Dis; 1992 Feb; 1(1):24-32. PubMed ID: 1365525
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylaxis for severe respiratory syncytial virus disease.
    Kupecz D
    Nurse Pract; 1996 Sep; 21(9):116-8. PubMed ID: 8884798
    [No Abstract]   [Full Text] [Related]  

  • 11. Respiratory syncytial virus immune globulin and conflict of interest.
    Groothuis JR
    N Engl J Med; 1998 Nov; 339(22):1644. PubMed ID: 9867534
    [No Abstract]   [Full Text] [Related]  

  • 12. The other effect of intravenously administered respiratory syncytial virus-enriched immune globulin for prophylaxis: less acute otitis media.
    Harrison CJ
    J Pediatr; 1996 Aug; 129(2):193-6. PubMed ID: 8765615
    [No Abstract]   [Full Text] [Related]  

  • 13. Respiratory syncytial virus PREVENT Study questions.
    Dransfield D; Kessler D; McCarthy C
    Pediatrics; 1997 Dec; 100(6):1044-5. PubMed ID: 9411387
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
    Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
    Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
    [No Abstract]   [Full Text] [Related]  

  • 15. Respiratory syncytial virus PREVENT Study questions.
    Moler FW
    Pediatrics; 1997 Dec; 100(6):1043-4; author reply 1045. PubMed ID: 9411385
    [No Abstract]   [Full Text] [Related]  

  • 16. Questions about palivizumab (Synagis).
    Lee SL; Robinson JL
    Pediatrics; 1999 Feb; 103(2):535; author reply 535-6. PubMed ID: 10026069
    [No Abstract]   [Full Text] [Related]  

  • 17. RSV-IGIV therapy: a cost/benefit analysis.
    Thakur BK; Wu LR; Schaeufele JF
    Pediatrics; 1997 Sep; 100(3 Pt 1):417-8. PubMed ID: 9304108
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of RespiGam at a university teaching hospital.
    Veerman M; Reuman P; Burchfield D; Sherman J
    Pediatrics; 1997 Jul; 100(1):160-1. PubMed ID: 9229713
    [No Abstract]   [Full Text] [Related]  

  • 19. Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.
    Robinson JL
    Curr Med Res Opin; 2009 Jul; 25(7):1631-2; author reply 1632-3. PubMed ID: 19480611
    [No Abstract]   [Full Text] [Related]  

  • 20. Questions about palivizumab (Synagis).
    Eppes SC
    Pediatrics; 1999 Feb; 103(2):534-5; author reply 535-6. PubMed ID: 10026068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.